Latest Breaking News On - Jacobus pharmaceuticals - Page 1 : comparemela.com

DON EMMERT/AFP via Getty Images In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after the manufacturer of a rival medicine claimed that Health Canada had originally issued an “incorrect and unreasonable” endorsement. In a 63-page ruling, Justice Martine St-Louis set aside the approval issued by the regulator last year. As a result, the government will now have to review the marketing file submitted by Jacobus Pharmaceuticals, a small, family-run company that sells a drug to treat people with a rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS. A competitor, Catalyst Pharmaceuticals (CPRX), is seeking to push back the approval until 2028. We asked Jacobus and Health Canada for comment and will update you accordingly.

United statesCanada federal courtCatalyst pharmaceuticalsHealth canadaJacobus pharmaceuticalsFederal courtJustice martine st louisWall streetSilicon valleyஒன்றுபட்டது மாநிலங்களில்கனடா கூட்டாட்சியின் நீதிமன்றம்வினையூக்கி மருந்துகள்ஆரோக்கியம் கனடாஜாகோபஸ் மருந்துகள்கூட்டாட்சியின் நீதிமன்றம்சுவர் தெரு